Appeal No. 2005-1797 Page 2
Application No. 09/954,975
subject an amount of a gallium composition effective to inhibit HIV
replication.
32. A method of reducing virus burden in a human subject infected with
human immunodeficiency virus (HIV) comprising administering to said
subject an amount of a gallium composition effective to inhibit HIV
replication.
35. A method of inhibiting development of acquired immunodeficiency
syndrome in a human subject infected with human immunodeficiency
virus (HIV) comprising administering to said subject an amount of a
gallium composition effective to inhibit HIV replication.
The references relied upon by the examiner are:
Murrer et al. (Murrer) 5,093,134 Mar. 3, 1992
Collery et al. (Collery) 5,525,598 Jun. 11, 1996
Bernstein 5,883,088 Mar. 16, 1999
Narsimhan, “The effect of copper and gallium compounds on ribonucleotide
reductase,” Abstract and p. 99 (UMI Dissertation Services) (1993).
GROUNDS OF REJECTION
Claims 11-13 and 16-40 stand rejected under 35 U.S.C. § 103. As
evidence of obviousness the examiner relies on the combination of Murrer,
Narasimhan, and appellants’ acknowledged prior art.
Claims 11-40 stand rejected under 35 U.S.C. § 103. As evidence of
obviousness the examiner relies on the combination of Narasimhan, Collery,
Bernstein, and appellants’ acknowledged prior art.
We affirm the rejection of claims 11-40 under 35 U.S.C. § 103 over the
combination of Narasimhan, Collery, Bernstein and appellants’ acknowledged
prior art. Having disposed of all claims on appeal, we do not reach the merits of
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007